Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have received a consensus recommendation of “Moderate Buy” from the four brokerages that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $11.50.

A number of equities research analysts recently issued reports on the stock. JMP Securities restated a “market outperform” rating and issued a $18.00 target price on shares of Inovio Pharmaceuticals in a report on Friday. Oppenheimer cut their price objective on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a report on Monday, November 18th. Royal Bank of Canada reduced their price target on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research report on Friday, November 15th. Finally, HC Wainwright reduced their target price on shares of Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating on the stock in a report on Monday, November 18th.

Inovio Pharmaceuticals Price Performance

Shares of NASDAQ:INO traded down $0.09 during midday trading on Friday, reaching $2.00. The company’s stock had a trading volume of 389,727 shares, compared to its average volume of 1,836,585. The business has a 50 day moving average price of $3.49 and a 200 day moving average price of $6.15. Inovio Pharmaceuticals has a 1 year low of $1.74 and a 1 year high of $14.75.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets grew its position in shares of Inovio Pharmaceuticals by 177.0% during the third quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 3,630 shares in the last quarter. SG Americas Securities LLC acquired a new position in Inovio Pharmaceuticals during the 3rd quarter worth $71,000. The Manufacturers Life Insurance Company bought a new stake in shares of Inovio Pharmaceuticals in the 2nd quarter worth about $82,000. MetLife Investment Management LLC raised its stake in shares of Inovio Pharmaceuticals by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 8,546 shares in the last quarter. Finally, Atom Investors LP bought a new position in shares of Inovio Pharmaceuticals during the third quarter worth about $103,000. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.